Austar Lifesciences Limited (AUSTAR) filed its Monthly Return for Equity Issuer for the period ended 31 July 2026, showing no changes in share capital structure or outstanding equity instruments.
The company’s authorised share capital remained at 10.00 billion ordinary shares with a par value of HKD 0.01 each, equivalent to HKD 100.00 million. Issued share capital was unchanged at 512.58 million ordinary shares, and the company held no treasury shares.
AUSTAR reported no activity in share options, warrants, convertible securities or other equity-linked agreements during the month, indicating no dilution events.
Management confirmed that the public float continues to meet the Main Board’s minimum 25% requirement, ensuring compliance with Hong Kong Stock Exchange listing rules.
The monthly return was submitted on 6 August 2026 and signed by Company Secretary Mak Yuk Kiu.
Comments